Related Experiment Videos
Potency after permanent prostate brachytherapy for localized prostate cancer.
Summary
Transperineal permanent prostate brachytherapy (PPB) shows lower 5-year potency rates than expected, except for monotherapy. Sildenafil improved erectile function in most patients, especially those not receiving neoadjuvant androgen deprivation.
Area of Science:
- Oncology
- Urology
- Radiotherapy
Background:
- Localized prostate cancer treatment often impacts sexual potency.
- Transperineal permanent prostate brachytherapy (PPB) is a common treatment modality.
- Understanding long-term potency preservation is crucial for patient quality of life.
Purpose of the Study:
- To evaluate potency preservation rates after transperineal permanent prostate brachytherapy (PPB) for localized prostate cancer.
- To assess the efficacy of sildenafil in improving erectile function post-PPB treatment.
- To identify factors influencing potency preservation and sildenafil response.
Main Methods:
- Prospective follow-up of 482 patients with localized prostate cancer treated with PPB.
- Actuarial analysis to determine time-dependent potency preservation rates.
- Evaluation of sildenafil efficacy in a subset of patients experiencing erectile dysfunction.
Main Results:
- The 5-year actuarial potency rate was 52.7% overall.
- Potency rates varied significantly based on treatment combinations: PPB monotherapy (76%), EBT + PPB (56%), NAAD + PPB (52%), and EBT + PPB + NAAD (29%).
- Neoadjuvant androgen deprivation (NAAD) and patient age were predictors of impotence. Sildenafil was effective in 62% of patients, with better outcomes in those not receiving NAAD.
Conclusions:
- Actuarial 5-year potency rates following PPB are generally lower than previously reported, with monotherapy showing the best outcomes.
- Sildenafil demonstrates significant efficacy in restoring erectile function for a majority of patients treated with PPB.
- Treatment de-escalation, avoiding NAAD when possible, may help preserve potency.